期刊
DRUG RESISTANCE UPDATES
卷 14, 期 2, 页码 88-94出版社
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.drup.2011.01.006
关键词
Antibiotics; Resistance; Pharmaceutical innovation; Drug development; Value chain
资金
- Medical Research Council [G0600810] Funding Source: researchfish
- Medical Research Council [G0600810] Funding Source: Medline
- MRC [G0600810] Funding Source: UKRI
In the face of a growing global burden of resistance to existing antibiotics, a combination of scientific and economic challenges has posed significant barriers to the development of novel antibacterials over the past few decades. Yet the bottlenecks at each stage of the pharmaceutical value chain from discovery to post-marketing present opportunities to reengineer an innovation pipeline that has fallen short. The upstream hurdles to lead identification and optimization may be eased with greater multi-sectoral collaboration, a growing array of alternatives to high-throughput screening, and the application of open source approaches. Product development partnerships and South-South innovation platforms have shown promise in bolstering the R&D efforts to tackle neglected diseases. Strategies that delink product sales from the firms' return on investment can help ensure that the twin goals of innovation and access are met. To effect these changes, both public and private sector stakeholders must show greater commitment to an R&D agenda that will address this problem, not only for industrialized countries but also globally. (C) 2011 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据